Far­al­lon says it's won all de­sired board seats from Ex­elix­is af­ter share­hold­er vote

Less than two months af­ter Far­al­lon Cap­i­tal Man­age­ment launched a proxy fight to gain con­trol of three seats on can­cer biotech Ex­elix­is’ board, it got what it want­ed at the com­pa­ny’s an­nu­al share­hold­er meet­ing.

The hedge fund said Wednes­day that pre­lim­i­nary re­sults at Ex­elix­is’ an­nu­al share­hold­er meet­ing elect­ed all three of Far­al­lon’s can­di­dates to the board: Tom Hey­man, Dave John­son and Bob Oliv­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER